Adverse effect analysis of high-intensity focused ultrasound in the treatment of benign uterine diseases

Liu Y, Yunchang Liu, Zhang WW, Wendy Wenyi Zhang, Min He, He M, Chunmei Gong, Gong C, Xie B, Bin Xie, Xiangxia Wen, Wen X, Li D, Dandan Li, Zhang L, Lian Zhang
International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group · 2018 · vol. 35(1) , pp. 56–61 · doi:10.1080/02656736.2018.1473894 · PMID:29792359 · W2803481785
article OA: hybrid CC0 ⤵ 22 in-corpus citations
📄 Open PDF View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by claude@2026-06, 2026-06-28 ⓘ

This retrospective analysis of 27,053 patients found that high-intensity focused ultrasound for benign uterine diseases had a major adverse event rate of 0.3844%, which decreased over time and was comparable across different conditions.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

OBJECTIVE: To retrospectively analyze the adverse effects of high-intensity focused ultrasound (HIFU) in management of benign uterine diseases. MATERIALS AND METHODS: From 2011 to 2017, 27,053 patients with benign uterine diseases were treated with HIFU in 19 centers in China. Among them, 17,402 patients had uterine fibroids, 8434 had adenomyosis, 876 had caesarean scar pregnancies, and 341 had placenta accreta. RESULTS: , respectively. After HIFU treatment, 13,170 adverse events were observed. Based on society of interventional radiology classification system, these adverse events were classified as Class A (47.5030%), Class B (0.7947%), Class C (0.3327%), and Class D (0.0518%). The rate of major adverse effects (Class C&D) was 0.3844%. Major adverse effects include skin burn, leg pain, vaginal discharge or bleeding, urinary retention, acute cystitis, intrauterine infection, bowel injury, acute renal failure, deep vein thrombosis, pubic symphysis injury, post-HIFU thrombocytopenia, sciatic nerve injury, and hydronephrosis. In 2011, the annual rate of major adverse effects was 0.9565%; the incidence decreased to 0.2852% in 2017. No significant difference was observed in the rates of major adverse effects between patients with uterine fibroids, adenomyosis and placenta accreta. CONCLUSIONS: Based on the results with low rate of major adverse effects from multiple centers, we concluded that HIFU is safe in treating patients with benign uterine diseases. With development of this technique and more experience on the part of the physicians, the rates of the major adverse effects will be further lowered.

My notes (saved in your browser only)

Condition tags

adenomyosis

MeSH descriptors

High-Intensity Focused Ultrasound Ablation Uterine Diseases Uterine Diseases Adult Female High-Intensity Focused Ultrasound Ablation High-Intensity Focused Ultrasound Ablation Humans Middle Aged Treatment Outcome Uterine Diseases Uterine Diseases

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (20)

Cited by (24)

Source provenance

europepmc
last seen: 2026-07-28T06:14:09.330459+00:00
openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-05-13T22:19:49.066213+00:00
License: CC0 · commercial use OK